Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical
company focused on developing next-generation biologic drugs and novel
oncology therapeutics, today provided an update on recent patent grants
and allowances worldwide.
Since May 2014, the Company has been issued 10 patents, including six in
the U.S., two in Japan and one each in New Zealand and India. In
addition, 13 patents have been allowed, including seven in the U.S., two
each in Japan and South Korea, and one each in Russia and Canada.
Xenetic Biosciences now has over 140 issued patents worldwide and
approximately 80 pending patents.
Select key patents issued recently by the U.S. Patent and Trademark
Office include Patent No. 8,796,207, Derivatisation of erythropoietin
(EPO), which relates to novel polysaccharide derivatives of EPO and
methods for producing such derivatives. The derivatives are useful for
improving the stability, pharmacokinetics and pharmacodynamics of EPO.
This same patent was also issued in Japan during the third quarter.
U.S. Patent No. 8,735,557, Activated sialic acid derivatives for
protein derivatisation and conjugation, was also recently granted
and relates to polysialic acid and derivatives of polysialic acids which
have terminal sialic acid units. This patent covers the targeted
conjugation of polysialic acid and its derivatives to therapeutics such
as peptides, proteins, drugs, drug delivery systems, etc.
Also issued during the third quarter was U.S. Patent No. 8,828,405, Method
to Enhance an Immune Response of Nucleic Acid Vaccination. This
patent relates to a composition comprising liposomes associated with a
nucleic acid operatively encoding an antigenic protein and with an
assistor protein. The composition provides an improved immune response
compared with mixtures of liposomes, some of which are associated with
the nucleic acid and some of which are associated with the assistor
protein.
“Xenetic Biosciences has a substantial patent portfolio to rival any
biotech company many times our size. This work results directly from our
previous strategy focused on research. Now that we have transformed into
a clinical development company, we are well positioned for potentially
monetizing our extensive intellectual property portfolio. We expect to
add 13 additional patents over the next three months,” said M. Scott
Maguire, chief executive officer of Xenetic Biosciences. “We are
particularly pleased with our intellectual property position in Japan as
those patent grants are typically difficult to secure. Our IP relates
not only to our ‘bio-better’ EPO, our lead candidate, but also to
improving availability of a number of protein-based drugs. We recently
received an allowance for a U.S. patent relating to novel polysaccharide
derivatives of granulocyte colony-stimulating factor (GCSF) and methods
for producing such derivatives. The derivatives are useful for improving
the stability, pharmacokinetics and pharmacodynamics of GCSF. Our
expectations are that we will have strong intellectual property
protection for many years after our lead compounds have progressed
through the U.S. regulatory process,” Mr. Maguire added.
About Xenetic Biosciences
Xenetic Biosciences is a biopharmaceutical company developing
next-generation biologic drugs and novel oncology therapeutics.
Xenetic's proprietary drug technology platforms include PolyXen® for
creating next-generation biologic drugs by extending the efficacy,
safety and half-life of biologic drugs, and OncoHist® for the
development of novel oncology drugs focused on orphan indications.
Xenetic's lead product candidates include ErepoXen®, an improved,
polysialylated form of erythropoietin (EPO) for the treatment of anemia
in pre-dialysis patients with chronic kidney disease, and OncoHist®, a
recombinant human histone H1.3 molecule which Xenetic is developing for
the treatment of refractory acute myeloid leukemia (AML). Xenetic is
developing a novel series of polysialylated blood coagulation factors
through its license agreement with Baxter International Inc. Xenetic is
also developing a broad pipeline of clinical candidates for
next-generation biologics and novel oncology therapeutics in a number of
orphan disease indications. For more information, please visit www.xeneticbio.com.
Copyright Business Wire 2014